The Journey of Drug Discovery
Past lessons, future innovations
Prasanthi Sadhu, Editor, Pharma Focus Asia
The field of drug discovery is a testament to human ingenuity and perseverance. Over the years, extraordinary breakthroughs have revolutionised healthcare, saved innumerable lives, and expanded the horizons of medical science. However, the path from identifying a therapeutic target to bringing a safe and effective drug to market has always been riddled with challenges — scientific, regulatory, and financial.
Reflecting on the history of drug discovery, we see a narrative of relentless progress, defined by milestones that have transformed our approach to treating disease. From the accidental discovery of penicillin to the development of high-throughput screening and the emergence of biotechnology, each era has introduced new tools and methodologies that have driven the industry forward. We've witnessed the rise of personalised medicine, the growing influence of big data and artificial intelligence, and a shift towards more targeted therapies, offering the promise of greater efficacy with fewer side effects.
But as we reflect on past achievements, we must also acknowledge the challenges that lie ahead. The demands on the pharmaceutical industry have never been higher, with a pressing need for faster, more cost-effective drug development, and an intensified focus on addressing unmet medical needs. The landscape is growing increasingly complex, marked by regulatory challenges, pricing pressures, and a heightened emphasis on sustainability and ethical considerations.
Looking ahead, the future of drug discovery will depend on our capacity to innovate and adapt. Breakthroughs in genomics, proteomics, and systems biology are unlocking new possibilities, while digital technologies are revolutionising
every stage of the process, from early research to clinical trials. Collaboration will be crucial—between academia and industry, across various disciplines, and spanning international borders.
In this issue, Mahesh Narayan FRSC Biophysicist Chief, Biochemistry Division, Department of Chemistry and Biochemistry, University of Texas elaborates on the cusp of a revolution in drug-discovery, driven by the AI/ML catalysed the marriage between the prediction of biological structures (proteins, DNA, RNA and heteromorphs thereof) across the biome and the techniques for accelerating the discovery, synthesis and development of small-molecule agonists and antagonists against them.
As we navigate this rapidly changing landscape, one thing remains clear: the quest to discover new therapies is as vital as ever. The challenges are significant, but so too are the possibilities. Together, we have the opportunity to shape a future where innovative medicines continue to improve and save lives.
Author Bio
Prasanthi Sadhu, Editor, Pharma Focus Asia
